Healthcare and Life Science
Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss
Mogrify Limited, a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, and Astellas Pharma Inc., a leader in regenerative medicine, today announced that they have executed a collaborative research agreement on in vivo re...
Deloitte appoints new senior partner for the South East region covering Cambridge, St Albans and Ipswich
Deloitte has appointed Fran Cousins as the new senior partner for the South East region - the first woman to hold this senior position in the region. ...
Guardtech Group support Ugandan COVID battle with CleanCube mobile lab donation
Suffolk-based cleanroom construction company gifts £50,000 laboratory van for critical PCR testing ...
Arecor announces presentation at EASD 2022 of Phase I clinical trial of AT278 ultra-concentrated ultra-rapid acting insulin for diabetes
Arecor Therapeutics plc, a globally focused biopharmaceutical company advancing today’s therapies to enable healthier lives, announces that its abstract titled “Phase I study investigating PK and PD of highly-concentrated insulin aspart AT278 U500” has been selected for presentation as ...
eg technology renew sponsorship of 2022 EIT Health Catapult
eg technology are pleased to announce they have renewed their sponsorship of the coveted EIT Health Catapult, in association with EIT Health. ...
Change Management doesn’t change the one thing you most need to change
High Performance Change says: If you wanted to drive across Australia, you’d pack the vehicle with a survival kit – to help you adapt to any situation you might find yourself in – before you departed. It would be utter madness to even think about just setting off as if it were a normal ...
Opportunities in China’s beauty value economy
What are the drivers for the phenomenal growth in China's hair care, anti-aging, and aesthetic medicine and cosmetic surgery markets? ...
LG Chem renews license triggering payment to Avacta
LG Chem will now proceed with Investigational New Drug (IND) enabling studies for Affimer PD-L1 antagonist programme ...
Charity Shop Manager shares her story
Arthur Rank Hospice Charity Shop Manager, Billie, shares her personal story ahead of the Chariots of Fire Repay Race in Cambridge 2022 ...
Avacta announces second dose escalation in the Phase I clinical study of AVA6000 Pro-doxorubicin
Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces that the first-in-human Phase I trial (ALS-6000-101) of AVA6000 Pro-doxorubicin will advance to the third dose...